Medincell says Teva wins FDA approval for WELTRUZA olanzapine monthly injection

Bitget2026/10/09 11:56

FDA cleared Teva’s WELTRUZA (olanzapine) once-monthly subcutaneous long-acting injectable for adults with schizophrenia, using Medincell technology. Product launch in the U.S. expected in coming weeks; Medincell to receive mid- to high-single-digit royalties on worldwide net sales. Approval triggers a $4 million milestone payment; additional commercial milestones total up to $105 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009150047) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact

FXStreet•2026/10/26 05:33

European morning quotes - Elections, central bank policies, and earnings reports will be in focus

路透社•2026/10/26 04:41

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41